A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

Sharanya Sivanand, Samuel Peña-Llopis, Hong Zhao, Blanka Kucejova, Patrick Spence, Andrea Pavia-Jimenez, Toshinari Yamasaki, David J. McBride, Jessica Gillen, Nicholas C. Wolff, Lorraine Morlock, Yair Lotan, Ganesh Raj, Arthur I Sagalowsky, Vitaly Margulis, Jeffrey A Cadeddu, Mark T. Ross, David R. Bentley, Wareef Kabbani, Xian-Jin Xie & 3 others Payal Kapur, Noelle S Williams, James B Brugarolas

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Most anticancer drugs entering clinical trials fail to achieve approval from the U.S. Food and Drug Administration. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug. Tumor samples from 94 patients were implanted in the kidneys of mice without additives or disaggregation. Tumors from 35 of these patients formed tumorgrafts, and 16 stable lines were established. Samples from metastatic sites engrafted at higher frequency than those from primary tumors, and stable engraftment of primary tumors in mice correlated with decreased patient survival. Tumorgrafts retained the histology, gene expression, DNA copy number alterations, and more than 90% of the protein-coding gene mutations of the corresponding tumors. As determined by the induction of hypercalcemia in tumorgraft-bearing mice, tumorgrafts retained the ability to induce paraneoplastic syndromes. In studies simulating drug exposures in patients, RCC tumorgraft growth was inhibited by sunitinib and sirolimus (the active metabolite of temsirolimus in humans), but not by erlotinib, which was used as a control. Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus. The routine incorporation of models recapitulating the molecular genetics and drug sensitivities of human tumors into preclinical programs has the potential to improve oncology drug development.

Original languageEnglish (US)
Article number137ra75
JournalScience Translational Medicine
Volume4
Issue number137
DOIs
StatePublished - Jun 6 2012

Fingerprint

Renal Cell Carcinoma
Pharmaceutical Preparations
Neoplasms
Sirolimus
Paraneoplastic Syndromes
Drug Evaluation
Hypercalcemia
United States Food and Drug Administration
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
Molecular Biology
Histology
Clinical Trials
Kidney
Gene Expression
Mutation
Survival
DNA
Growth
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. / Sivanand, Sharanya; Peña-Llopis, Samuel; Zhao, Hong; Kucejova, Blanka; Spence, Patrick; Pavia-Jimenez, Andrea; Yamasaki, Toshinari; McBride, David J.; Gillen, Jessica; Wolff, Nicholas C.; Morlock, Lorraine; Lotan, Yair; Raj, Ganesh; Sagalowsky, Arthur I; Margulis, Vitaly; Cadeddu, Jeffrey A; Ross, Mark T.; Bentley, David R.; Kabbani, Wareef; Xie, Xian-Jin; Kapur, Payal; Williams, Noelle S; Brugarolas, James B.

In: Science Translational Medicine, Vol. 4, No. 137, 137ra75, 06.06.2012.

Research output: Contribution to journalArticle

Sivanand, S, Peña-Llopis, S, Zhao, H, Kucejova, B, Spence, P, Pavia-Jimenez, A, Yamasaki, T, McBride, DJ, Gillen, J, Wolff, NC, Morlock, L, Lotan, Y, Raj, G, Sagalowsky, AI, Margulis, V, Cadeddu, JA, Ross, MT, Bentley, DR, Kabbani, W, Xie, X-J, Kapur, P, Williams, NS & Brugarolas, JB 2012, 'A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma', Science Translational Medicine, vol. 4, no. 137, 137ra75. https://doi.org/10.1126/scitranslmed.3003643
Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Science Translational Medicine. 2012 Jun 6;4(137). 137ra75. https://doi.org/10.1126/scitranslmed.3003643
Sivanand, Sharanya ; Peña-Llopis, Samuel ; Zhao, Hong ; Kucejova, Blanka ; Spence, Patrick ; Pavia-Jimenez, Andrea ; Yamasaki, Toshinari ; McBride, David J. ; Gillen, Jessica ; Wolff, Nicholas C. ; Morlock, Lorraine ; Lotan, Yair ; Raj, Ganesh ; Sagalowsky, Arthur I ; Margulis, Vitaly ; Cadeddu, Jeffrey A ; Ross, Mark T. ; Bentley, David R. ; Kabbani, Wareef ; Xie, Xian-Jin ; Kapur, Payal ; Williams, Noelle S ; Brugarolas, James B. / A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. In: Science Translational Medicine. 2012 ; Vol. 4, No. 137.
@article{cd84697ebb324d6cbb89ee55c99f9379,
title = "A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma",
abstract = "Most anticancer drugs entering clinical trials fail to achieve approval from the U.S. Food and Drug Administration. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug. Tumor samples from 94 patients were implanted in the kidneys of mice without additives or disaggregation. Tumors from 35 of these patients formed tumorgrafts, and 16 stable lines were established. Samples from metastatic sites engrafted at higher frequency than those from primary tumors, and stable engraftment of primary tumors in mice correlated with decreased patient survival. Tumorgrafts retained the histology, gene expression, DNA copy number alterations, and more than 90{\%} of the protein-coding gene mutations of the corresponding tumors. As determined by the induction of hypercalcemia in tumorgraft-bearing mice, tumorgrafts retained the ability to induce paraneoplastic syndromes. In studies simulating drug exposures in patients, RCC tumorgraft growth was inhibited by sunitinib and sirolimus (the active metabolite of temsirolimus in humans), but not by erlotinib, which was used as a control. Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus. The routine incorporation of models recapitulating the molecular genetics and drug sensitivities of human tumors into preclinical programs has the potential to improve oncology drug development.",
author = "Sharanya Sivanand and Samuel Pe{\~n}a-Llopis and Hong Zhao and Blanka Kucejova and Patrick Spence and Andrea Pavia-Jimenez and Toshinari Yamasaki and McBride, {David J.} and Jessica Gillen and Wolff, {Nicholas C.} and Lorraine Morlock and Yair Lotan and Ganesh Raj and Sagalowsky, {Arthur I} and Vitaly Margulis and Cadeddu, {Jeffrey A} and Ross, {Mark T.} and Bentley, {David R.} and Wareef Kabbani and Xian-Jin Xie and Payal Kapur and Williams, {Noelle S} and Brugarolas, {James B}",
year = "2012",
month = "6",
day = "6",
doi = "10.1126/scitranslmed.3003643",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "137",

}

TY - JOUR

T1 - A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

AU - Sivanand, Sharanya

AU - Peña-Llopis, Samuel

AU - Zhao, Hong

AU - Kucejova, Blanka

AU - Spence, Patrick

AU - Pavia-Jimenez, Andrea

AU - Yamasaki, Toshinari

AU - McBride, David J.

AU - Gillen, Jessica

AU - Wolff, Nicholas C.

AU - Morlock, Lorraine

AU - Lotan, Yair

AU - Raj, Ganesh

AU - Sagalowsky, Arthur I

AU - Margulis, Vitaly

AU - Cadeddu, Jeffrey A

AU - Ross, Mark T.

AU - Bentley, David R.

AU - Kabbani, Wareef

AU - Xie, Xian-Jin

AU - Kapur, Payal

AU - Williams, Noelle S

AU - Brugarolas, James B

PY - 2012/6/6

Y1 - 2012/6/6

N2 - Most anticancer drugs entering clinical trials fail to achieve approval from the U.S. Food and Drug Administration. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug. Tumor samples from 94 patients were implanted in the kidneys of mice without additives or disaggregation. Tumors from 35 of these patients formed tumorgrafts, and 16 stable lines were established. Samples from metastatic sites engrafted at higher frequency than those from primary tumors, and stable engraftment of primary tumors in mice correlated with decreased patient survival. Tumorgrafts retained the histology, gene expression, DNA copy number alterations, and more than 90% of the protein-coding gene mutations of the corresponding tumors. As determined by the induction of hypercalcemia in tumorgraft-bearing mice, tumorgrafts retained the ability to induce paraneoplastic syndromes. In studies simulating drug exposures in patients, RCC tumorgraft growth was inhibited by sunitinib and sirolimus (the active metabolite of temsirolimus in humans), but not by erlotinib, which was used as a control. Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus. The routine incorporation of models recapitulating the molecular genetics and drug sensitivities of human tumors into preclinical programs has the potential to improve oncology drug development.

AB - Most anticancer drugs entering clinical trials fail to achieve approval from the U.S. Food and Drug Administration. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug. Tumor samples from 94 patients were implanted in the kidneys of mice without additives or disaggregation. Tumors from 35 of these patients formed tumorgrafts, and 16 stable lines were established. Samples from metastatic sites engrafted at higher frequency than those from primary tumors, and stable engraftment of primary tumors in mice correlated with decreased patient survival. Tumorgrafts retained the histology, gene expression, DNA copy number alterations, and more than 90% of the protein-coding gene mutations of the corresponding tumors. As determined by the induction of hypercalcemia in tumorgraft-bearing mice, tumorgrafts retained the ability to induce paraneoplastic syndromes. In studies simulating drug exposures in patients, RCC tumorgraft growth was inhibited by sunitinib and sirolimus (the active metabolite of temsirolimus in humans), but not by erlotinib, which was used as a control. Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus. The routine incorporation of models recapitulating the molecular genetics and drug sensitivities of human tumors into preclinical programs has the potential to improve oncology drug development.

UR - http://www.scopus.com/inward/record.url?scp=84862145477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862145477&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003643

DO - 10.1126/scitranslmed.3003643

M3 - Article

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 137

M1 - 137ra75

ER -